Work

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

Year: 2015

Type: erratum

Source: Investigational New Drugs

DOI: 10.1007/s10637-015-0287-6

Authors: Geoffrey I. Shapiro, Stewart McCallum, Laurel M. Adams, Laurie Sherman, Steve Weller, Suzanne Swann, Harold Keer, Dale Miles, Thomas Müller, Daniel C. Rabe, Fabiola Cecchi, Donald P. Bottaro, Patricia LoRusso

Institutions: Harvard University, Dana-Farber Cancer Institute, GlaxoSmithKline (United States), CSL (United States), Exelixis (United States), Astex Pharmaceuticals, Genentech, University of Chicago, National Cancer Institute, Center for Cancer Research, NantOmics LLC (United States), Wayne State University, Yale Cancer Center, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2123706118

Cites: 29

Cited by: 40

Related to: 10